Top Markets
#1 Black Phoenix Black Phoenix +732.42%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.50%
#3 MiL.k Alliance MiL.k Alliance +23.56%
#4 THORChain THORChain +21.03%
#5 Biconomy Biconomy +20.37%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +16.12%
#7 THORChain Yield THORChain Yield +15.47%
#8 MetaDAO MetaDAO +13.97%
#9 Moolah Moolah +12.70%
#10 Pons Pons +11.94%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
MBX Biosciences, Inc. Common Stock MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. Common Stock

MBX
Peringkat dalam Saham #4865
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical... MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Harga Saham
$67.63
Terakhir disinkronkan: 2026-08-26
Kapitalisasi Pasar
$3.22B
Perubahan (1 hari)
-1.45%
Perubahan (1 tahun)
372.57%
Negara
US
Perdagangan MBX Biosciences, Inc. Common Stock (MBX)

Kategori

Healthcare
Rasio P/E untuk MBX Biosciences, Inc. Common Stock (MBX)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari MBX Biosciences, Inc. Common Stock, rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk MBX Biosciences, Inc. Common Stock dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.